Aggressive prostate cancer study with HRR blood test
Part of Cancer, Kidney & urinary clinical trials.
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have metastatic prostate cancer that is still hormone-sensitive (not yet resistant to hormone therapy).
- Your cancer is high-aggressive, meaning a Gleason score of 8, 9, or 10.
- You have high-volume disease: at least 4 bone metastases (with one outside the spine/pelvis) or spread to internal organs.
- You have already had a tumor test that shows your HRR gene status (like BRCA).
- You have not taken part in any other research trial for prostate cancer since it spread.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
This study looks at whether a blood test that finds tiny amounts of remaining cancer (called minimal residual disease) can help predict how well treatment works for men with prostate cancer that has spread. If you qualify, you'll help researchers understand if this test can guide future treatment decisions.
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
This trial looks for specific DNA repair changes in men with prostate cancer. It tests if these genetic features can help guide treatment decisions. You may join if you have high-risk localized, newly metastatic, or advanced prostate cancer and have tissue available for testing.
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.